Indication for a Pneumocystis Prophylaxis Therapy in Patients with Vascular Anomalies Treated with PIK3/AKT/mTOR Pathway Inhibitors: Experts' Opinion and Systematic Review from the Literature.

Maxime Navarro,Aude Allemang-Trivalle,Sophie Leducq,Annie-Pierre Jonville-Bera,Anaïs Maurier, Tarik Zejli,Afi-Emiliène Edée, Emilie Harchaoui,Bruno Giraudeau,Annabel Maruani

Dermatology (Basel, Switzerland)（2023）

引用 0|浏览10

暂无评分

摘要

Our study shows that even if PJP is a rare event, it may occur in patients with VAs treated with an mTOR inhibitor. Although our results cannot allow for revising guidelines, prophylaxis with TMP-SMX might be appropriate for a subgroup of patients with risk factors for PJP.

查看译文

关键词

mTOR inhibitors, Sirolimus, Alpelisib, Vascular anomalies, Pneumocystis infection

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要